Home
Storia in 1 fonti
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss; Parabilis boosts IPO target to $553M net proceeds.
Raccontata da
endpoints.news
Timeline cronologica
- ·
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss; Parabilis boosts IPO target to $553M net proceeds.
- ·
Parabilis' $670M IPO sets new biotech record, will fund cancer drug
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.